StockNYSE · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$ZTS
Zoetis Inc.
Zoetis develops, manufactures and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health products for veterinarians, pet owners and livestock producers. Its portfolio serves dogs, cats, horses, cattle, swine, poultry, fish and sheep, and includes parasiticides, vaccines, dermatology products, anti-infectives, pain and sedation treatments, other pharmaceuticals and animal health diagnostics. Brands include Simparica, Apoquel, Cytopoint, Librela and Vetscan. Zoetis also provides contract manufacturing services to third parties and offers human health diagnostics products. Zoetis sells companion animal products primarily to veterinarians and veterinary distributors, and livestock products primarily to veterinarians, livestock producers and distributors. Some products are also sold through retail and e-commerce outlets. It operates in U.S. and International segments, directly markets products in approximately 45 countries, and sells them in more than 100 countries. Zoetis is headquartered in Parsippany, New Jersey.
Zoetis (ZTS) stock trades at a discount, with a P/E of 13.5x vs. 22.3x for the median S&P 500 company. It has lost 29.6% over the past year. Zoetis maintains high operating margins (37.7%) but faces slowing revenue growth (0.9% YoY) and declining dermatology sales. The company is introducing new pet medicine versions and offering discounts to combat market share loss.
Zoetis reported Q3 2026 revenue of $2.39 billion, beating estimates by 2.6%, and adjusted EPS of $1.75, beating by 15.8%. The company raised full-year revenue and EPS guidance. Operating margin declined due to competitive pressures in the dermatology segment and promotional investments. Livestock and diagnostics segments showed growth, with the latter driven by recent acquisitions and new product launches.
Zoetis reported Q3 earnings, noting slowed U.S. dermatology share loss due to promotional investments. Livestock revenue rose 7% to $797M, while companion animal diagnostics revenue increased 13% to $122M. The company updated its 2026 revenue outlook to $9.22B-$9.32B and raised adjusted net income and earnings forecasts. Zoetis expects U.S. approvals for Cytopoint and Simparica Duo by year-end and Lenivia in 2027.
via TradingView
ZTS sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ZTS (Zoetis Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ZTS coverage spans earnings, financial news and sector analysis.
What's driving ZTS
Guidance cut suggests lower near‑term earnings and revenue growth.
AlphAI scores every news story that mentions ZTS with an AI model for sentiment and relevance, and aggregates insider trades from Zoetis Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zoetis (ZTS) stock trades at a discount, with a P/E of 13.5x vs. 22.3x for the median S&P 500 company. It has lost 29.6% over the past year. Zoetis maintains high operating margins (37.7%) but faces slowing revenue growth (0.9% YoY) and declining dermatology sales. The company is introducing new pet medicine versions and offering discounts to combat market share loss.
Zoetis reported Q3 2026 revenue of $2.39 billion, beating estimates by 2.6%, and adjusted EPS of $1.75, beating by 15.8%. The company raised full-year revenue and EPS guidance. Operating margin declined due to competitive pressures in the dermatology segment and promotional investments. Livestock and diagnostics segments showed growth, with the latter driven by recent acquisitions and new product launches.
Zoetis reported Q3 earnings, noting slowed U.S. dermatology share loss due to promotional investments. Livestock revenue rose 7% to $797M, while companion animal diagnostics revenue increased 13% to $122M. The company updated its 2026 revenue outlook to $9.22B-$9.32B and raised adjusted net income and earnings forecasts. Zoetis expects U.S. approvals for Cytopoint and Simparica Duo by year-end and Lenivia in 2027.
Sen. Shelley Moore Capito (R-W.Va.) sold shares of Apple, Meta, Microsoft, and Zoetis in October, with three of the four being partial sales of Magnificent Seven stocks. She has made nearly 600 trades totaling $5.8 million since 2015, mostly selling stocks in recent years.
Rising veterinary costs, driven by advanced treatments, are increasing pet insurance adoption in the US. About 7 million pets were insured in 2025, up 9% from the previous year. Premiums are projected to reach $6.4 billion in 2026, with average annual veterinary spending at $560. Companies like Embrace Pet Insurance and Trupanion report growing claims and subscriptions. Zoetis and IDEXX Laboratories are among those providing advanced treatments and diagnostics.
Zoetis Inc. (ZTS) reported Q3 profit of $591M, or $1.44 per share, exceeding expectations. Revenue was $2.39B, also topping forecasts. The company raised full-year earnings guidance to $6.25-$6.35 per share and revenue to $9.22B-$9.32B.
NEOGEN CORP (NEOG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approva
Morgan Stanley kept its Overweight rating on Zoetis but reduced its price target to $82 from $85, a 3.5% decrease. The new target suggests a 5.4% upside from the Oct 28 closing price of $77.80. Recent analyst price targets for Zoetis range from $74 to $85.
Corcept (CORT) reported Q2 revenues of $256.1M, up 31.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing expectations. Bristol-Myers Squibb (BMY) reported $12.97B in revenues, up 5.7% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market focus has shifted from AI to geopolitics and back to fundamentals.
Zoetis (ZTS) stock is 45.1% below its 52-week high. The company's free cash yield is 6.8% of its market value, higher than the S&P 500 median. Zoetis faces challenges due to fewer pet vet visits and increased competition, leading to a revenue guidance cut. The stock trades at 12.9 times earnings, reflecting concerns about sustained cash flow growth and debt levels.